Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Reto Abele"'
Publikováno v:
Oncology. 51:84-86
Retinoids and interferon-alpha (IFN-alpha) have been shown to have a synergetic antiproliferative and differentiative effect on many cell lines, and in combination they have already been tested with some success in the treatment of some tumors. We in
Publikováno v:
Pathology international. 46(10)
The clinical and pathological findings are reported concerning a 73-year-old woman with progressive metastatic carcinoma of the left breast, who developed interfollicular Hodgkin's disease within the right cervical lymph nodes. Metastatic carcinoma a
Autor:
Reto Abele, Daniel Dupont, Evelyne Cumps, Daniel Kisner, Yvon Kenis, Pierre Dodion, Marcel Rozencweig, Martine Piccart
Publikováno v:
European Journal of Cancer and Clinical Oncology. 17:775-779
Ametantrone is a new aminoanthraquinone derivative that achieves antitumor activity in a large variety of animal models. It is a dark blue dye. In this phase I study, the drug was given as a 30-min i.v. infusion repeated every 2–3 weeks. Nineteen p
Autor:
Eduard E. Holdener, Pierre Alberto, Victor Hofmann, P. Siegenthaler, Reto Abele, Susanna Kaplan, Ryssel Hj, Diethelm Hartmann, Franco Cavalli
Publikováno v:
Journal of Clinical Oncology. 1:750-754
Doxifluridine, a new fluoropyrimidine derivative, was tested in a cooperative phase II trial by the Swiss Group for Clinical Cancer Research in advanced measurable colorectal cancer. The drug was given in a five consecutive day schedule by a bolus in
Autor:
Reto Abele, Robert de Jager, Franco Cavalli, Marcel Rozencweig, P. Siegenthaler, A. Clarysse, Heine H. Hansen, Georgette Renard, Antonio Brugarolas
Publikováno v:
European journal of cancerclinical oncology. 20(2)
A broad phase II trial of elliptinium was conducted in 105 evaluable patients with advanced solid tumors. The drug was given as a 60–90-min i.v. infusion at a weekly dose of 100 mg/m2. Of 36 breast cancer patients, one achieved complete and six ach
Autor:
Paolo P. Bedogni, Yvon Kenis, Reto Abele, Jean-Jacques Body, Luigi Lenaz, Steven D. Reich, Stanley T. Crooke, Marcel Rozencweig
Publikováno v:
European journal of cancer. 16(12)
Carminomycin is a new anthracycline derivative. In this phase I trial, the drug was given i.v. every 3–4 weeks to 19 patients with solid tumors. Thirty-five courses of therapy were given. Leucopenia was dose-related and dose-limiting with a steep d
Autor:
Franco Cavalli, Pierre Dodion, Georgette Renard, Stein Gundersen, Martine Van Glabbeke, Reto Abele, Michel Clavel
Publikováno v:
European Journal of Cancer and Clinical Oncology. 23:251-252